Let their light shine with JEMPERLI (dostarlimab-gxly)1

The first and only immunotherapy approved in combination with carboplatin and paclitaxel to treat dMMR/MSI-H primary advanced or recurrent endometrial cancer.1

Blue  light bulb icon

Dostarlimab-gxly (JEMPERLI) in combination with carboplatin-paclitaxel is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a Category 1 preferred treatment option for primary or adjuvant therapy for stage III-IV* dMMR/MSI-H endometrial carcinoma or as a first-line therapy option for dMMR/MSI-H recurrent disease.2

Category 1 – Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

  • * For stage IIIA, IIIB, or IIIC1 with measurable disease, stage IIIC1 with carcinosarcoma, clear-cell, serous, or mixed histology regardless of the presence of measurable disease, and stage IIIC2 or stage IV regardless of the presence of measurable disease.

dMMR=mismatch repair deficient; MSI-H=microsatellite instability-high; NCCN=National Comprehensive Cancer Network.

JEMPERLI RUBY Trial Results

Learn more about the RUBY trial results for JEMPERLI with Dr. Cecelia Boardman, MD

WATCH VIDEO

Uterus Icon

Endometrial cancer & dMMR

LEARN MORE ABOUT dMMR

Icon: JEMPERLI (dostarlimab-gxly) Safety Profile

Learn about the safety profile from the RUBY trial

SEE RUBY SAFETY PROFILE

Icon: JEMPERLI (dostarlimab-gxly) Safety Profile

Learn about the safety profile from the GARNET trial

SEE GARNET SAFETY PROFILE